Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Other financing activities: 2017-2021

Historic Other financing activities for Aclaris Therapeutics (ACRS) over the last 3 years, with Jun 2021 value amounting to $300,000.

  • Aclaris Therapeutics' Other financing activities rose 164.79% to $300,000 in Q2 2021 from the same period last year, while for Jun 2021 it was -$289,000, marking a year-over-year increase of 25.90%. This contributed to the annual value of -$377,000 for FY2024, which is 4612.50% down from last year.
  • Per Aclaris Therapeutics' latest filing, its Other financing activities stood at $300,000 for Q2 2021, which was up 1,067.74% from -$31,000 recorded in Q4 2020.
  • Aclaris Therapeutics' Other financing activities' 5-year high stood at $378,000 during Q1 2018, with a 5-year trough of -$753,000 in Q4 2017.
  • Its 3-year average for Other financing activities is -$46,889, with a median of -$31,000 in 2020.
  • Its Other financing activities has fluctuated over the past 5 years, first surged by 251.32% in 2019, then slumped by 2,472.22% in 2020.
  • Aclaris Therapeutics' Other financing activities (Quarterly) stood at -$753,000 in 2017, then skyrocketed by 89.91% to -$76,000 in 2018, then spiked by 251.32% to $115,000 in 2019, then slumped by 126.96% to -$31,000 in 2020, then spiked by 164.79% to $300,000 in 2021.
  • Its Other financing activities was $300,000 in Q2 2021, compared to -$31,000 in Q4 2020 and -$95,000 in Q3 2020.